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1 An industry in transition
The chemical and pharmaceutical industry is
an industry in transition. In the past, the chemical
industry always altered modern life through the
transformation of new scientific findings into mar-
ketable products.  Business historian Alfred Chan-
dler describes the success model of companies in
the chemical and pharmaceutical industry as fol-
lows: Successful companies transferred findings
from basic research into marketable products and
used the profits and learnings from each genera-
tion of new products to commercialize the next
generation (Chandler, 2005, p. 309). This model of
success is in question. Nowadays, companies have
to consider that science and technology essential
to the growth of high-technology companies might
stop being the engine for innovation and growth.
The chemical industry with its periods of research-
based growth between the 1880s and 1920s and
again during the 1940s and 1950s has to cope with
the situation that, since the 1950s, chemical sci-
ences and engineering have ceased to generate
major new product developments (Whitesides,
2015, p. 3196; Schröter, 2007, p. 57). As a result, prod-
uct and process development gain more impor-
tance for successful companies in the chemical
industry than basic research. For the pharmaceu-
tical industry, on the contrary, the success model
of generating new products through basic research
findings has not stopped yet: In the 1960s and 1970s,
biology and related disciplines – microbiology, enzy-
mology, and the beginnings of molecular biology
– were forming the new basis for additional new
products, and since the 1980s, new findings in the
field of biotechnology fuel the development of
innovative products on the basis of basic research
findings (“The Biotechnology Revolution”). Chan-
dler thus concludes that “in the beginning of the
twenty-first century, the chemical industry is no
longer a high-tech industry. Pharmaceuticals, how-
ever, remains a dynamic high-tech industry as
biotechnology is contributing to revolutionary
changes on the scale comparable to those of the
Second Industrial (…) Revolution (…) in the 1880s.”
2 Trends driving change
Different authors have been working on the
future of the chemical industry (Whitesides, 2015;
VCI, 2013; VNCI and Deloitte, 2012). Often, they have
analyzed the impact of so-called “megatrends” on
the future development of the industry. These long-
term trends are defined as drivers of change that
affect all parts of society (business, society, and pol-
itics), may have a global reach and typically last for
more than 20 years. With the help of these mega-
trends and their complex interplay, political insti-
tutions, industry associations or companies create
different scenarios in order to shape different pic-
tures of the future. Industry associations use these
pictures to communicate to politicians about poten-
tial opportunities and risks for an industry, compa-
nies to identify relevant fields for action, e.g. the
need for cost cutting in one division and the need
for investment in another. For managers, the mega-
trends serve as a common frame of reference when
analyzing the need of business transformation in
the chemical industry. 
There are different ways to group trends for the
chemical and pharmaceutical industry (cf. White-
sides, 2015; VCI, 2013; Johansson et al., 2012; Matlin
and Abegaz, 2011). A large-scale online survey (called
“From megatrends to business excellence”) ana-
lyzed the need for business transformation in the
chemical industry. In this survey, upcoming trends
– creating a potential need for transformation –
were addressed and participants asked about the
relevant management activities to cope with these
trends (for details see Utikal and Leker, 2015). In
total, 270 persons participated in the online sur-
vey; 141 participants having significant manage-
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ment experience in the chemical industry finished
the total questionnaire. Out of these, 34% consid-
ered themselves as being experts in the segment
of specialty chemicals, 16% in the field of polymers,
22% pharmaceuticals, 10% basis chemicals, 8% agro-
chemicals and 10% in other fields. 50% of the par-
ticipants are top-managers (board level), 20% are
expert in the field of research and development
and innovation, 25% have other leading positions
in chemical and pharmaceutical companies, and
5% hold other positions. Different company sizes
are reflected as well. The results of the survey have
been discussed in different workshops with man-
agers and have been the basis for expert interviews
with high-level executive managers from the chem-
ical and pharmaceutical industry.
Within this survey, participants were asked to
rate the importance of selected megatrends for
their business activities in the years 2014 and 2024
(see figure 1). We distinguished five topics and ten
trends: (1) Globalization and urbanization, (2) Cross-
industry and interdisciplinary innovation and tech-
nology, (3) Energy and resources, (4) New consump-
tion patterns, and (5) Demographic change/busi-
ness world in Europe.
Across all segments, the most important trends
for the year 2014 are:
1) Globalization: The most important and con-
tinuing trend is globalization. Participants
assume that especially the Asian market will
continue to increase in volume and value. Of
course, this has implications for the configura-
tion of the value chain and for the steering of
business activities.
2) Cross-industry and interdisciplinary innova-
tion: Participants state that innovations will still
be a key value driver, whereby they expect cross-
industry innovation or innovation based on inter-
disciplinary cooperation to gain further impor-
tance.
3) Higher qualification: Participants see an
increasing importance of higher qualification
for the chemical industry.
Figure 1 Importance of different trends for the chemical industry in the years 2014 and 2024 (Source: Industry Study „From          
megatrends to business excellence“ (2014); Question: How relevant are the following aspects in your opinion for   
the activities of your business unit/company in the year 2014 and 2024? (1 = not at all relevant – 7 = very relevant); 
Representation: Arithmetic average of answers).
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The chemical industry in Germany is thus get-
ting more international, it opens up to other sci-
entific disciplines and believes in the importance
of a highly skilled workforce to attain its goals. It
is interesting to see that for the year 2014, so-called
“green issues” – e.g. sustainable products, the shift
to alternative energy sources and the use of renew-
able resources – are considered to have the least
relevance out of all potential megatrends. At the
same time, participants assume these aspects to
be of increasing importance until the year 2024.
3 Fields of transformation
Can companies in the German chemical and
pharmaceutical industry be adequately transformed
in order to realize the opportunities inherent in the
outlined trends? Beyond the specific focus on the
chemical industry, this question has gained a lot of
attention in management literature on organiza-
tional change. Organizational change is defined as
a difference in form, quality, or state over time in
an organizational entity (Van de Ven and Poole,
1993, p. 512). Change processes can be analyzed for
multiple entities (e.g. for whole industries) or for a
single entity (e.g. a single company). One influen-
tial school analyzing change on the level of multi-
ple entities, is the population ecology school stat-
ing that the ability of a single entity to change is
very limited. This school proposes that a Darwin-
ian view describing change processes as a result of
variation, selection and retention may be adequate
to understand change processes (e.g. Hannan and
Freeman, 1986). The opposite position is taken by
the school of planned change. The planned change
model views developments on the level of the sin-
gle organization as a result of an active organiza-
tion design process where decision makers formu-
late goals, implement measures and evaluate the
impact of these measures on the defined goals (for
the different models see e.g. Van de Ven and Sun,
2011). In the following, organizational change is
examined from the perspective of a single compa-
ny. The reasoning is based on the assumption that
companies and acting managers have some dis-
cretion in actively designing change processes.
Organizational change processes can be further
characterized with regard to their intensity as incre-
mental or radical changes. Incremental changes
encompass minor modifications of the status quo,
radical changes have a profound impact on differ-
ent fields of an organization (Levy and Merry, 1986). 
The participants of the survey “From mega-
trends to business excellence” evaluated to what
degree their business unit or company would have
to change in the light of the above-mentioned
trends (need for change) as well as to what degree
the respective unit is already prepared for this
upcoming change (degree of preparation). Across
all segments, participants identified a medium need
for change. The respondents are thus expecting –
on average – more evolutionary than revolution-
ary change for their companies. The degree of prepa-
ration corresponded – only looking at the means
of the answers – to the needed change. Addition-
ally, different fields for change were addressed: The
participants identified a medium need for change
of their company’s strategy and business model
and the existing business processes; here they con-
sidered their companies as being sufficiently pre-
pared. However, in the fields of workforce qualifi-
cation and company culture, the respondents iden-
tified a relevant discrepancy between the need for
change and the degree of preparation. This aspect
can be further explored in a segment-specific analy-
sis (see figure 2), whereby the split by industry seg-
ments reveals the following interesting differences: 
In the field of base chemicals, respondents iden-
tify compared to all other segments the lowest
need for change but the highest degree of prepa-
ration. This can be interpreted as a sign for
respondents considering their business as being
stable and already highly optimized. They focus
on process innovations and select their produc-
tion site based on global market demand on
the one hand and energy and raw material costs
on the other hand. They do not see any far-reach-
ing shift in their energy and raw material basis
away from fossil fuels until the year 2024. From
the perspective of the respondents, these two
drivers will not heavily influence existing oper-
ations – even though they are often cited in
research and policy publications as extremely
relevant trends for the industry segment. 
In the area of specialty chemistry, a higher need
for change can be observed. Overall, the degree
of preparation corresponds to the needed
change, but discrepancies exist in the field of
workforce qualification and corporate culture.
Obviously, the participants assume that the
expected changes in the field of cross-industry
and interdisciplinary innovation (identified as
very important trends for this segment) imply
changes on the side of workforce qualification
and the company’s values. The conducted expert
interviews additionally revealed that compa-
nies in the specialty chemical segment face chal-
lenges in implementing the desired change from
a product to a solution provider: Given the high
complexity and diversity of value chains on the
side of their customers, employees have diffi-
culties in determining and quantifying the spe-
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cific value their products provide in these dif-
ferent value chains. With regard to cross-indus-
try collaborations in innovation projects, man-
agers identify a lack of knowledge about part-
ners and uncertainties in handling different
industry cultures as main deficits. Some com-
panies manage the needed adaptation proac-
tively: For instance, the specialty chemical com-
pany Clariant organizes workshops with poten-
tial customers in order to get a deep under-
standing of customer requirements. After the
ideation phase, the management mode changes
in order to guarantee a short time-to-market.
This opening up of the innovation process is a
new development. 
With regard to the pharmaceutical segment,
the biggest need for change and the lowest
degree of preparation was stated. A high demand
for change is shown across the fields corporate
culture, employee qualification, strategy/busi-
ness model and business processes. Compared
with the other segments, it is interesting to see
that for pharmaceuticals – with the exception
of the topic strategy/business model – the
degree of preparation is much lower than the
needed change. This holds not only true for the
so-called “soft issues” of corporate culture and
workforce qualification but as well for the “hard”
fields of business processes. In the expert inter-
views, this was explained by regulatory require-
ments decisive for the pharmaceutical indus-
try. These requirements increase costs for con-
tinuous process optimizations and sometimes
may even prevent them. Some pharmaceutical
companies open up their research and produc-
tion activities and cooperate more than in the
past with partners – this change has to be
accompanied with a change of the corporate
culture as well. 
4 Managing evolutionary change
One central conclusion from the study “From
megatrends to business excellence” is that com-
panies in the chemical industry do not see the need
for a short-term, radical change. This holds true –
to a lower degree – for pharmaceutical companies
as well. Regarding the intensity of change, compa-
nies in the chemical and pharmaceutical industry
thus differ significantly from companies in other
industries, such as the financial, publishing or music
industries. These sectors are confronted with dis-
ruptive change initiated by the internet which pro-
Figure 2 Business transformation in the chemical industry: Segment-specific perspective (Source: Industry Study „From 
megatrends to business excellence“ (2014); Questions: Given the megatrends, how large is from your perspective  
the need for business transformation in your business unit/ your company? (1 = very small; 7 = very large) How 
well is your business unit/your company prepared for the change in different fields? (1 = very poorly; 7 = very 
well); Representation: Arithmetic average of answers).
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foundly puts established business models into ques-
tion. Single chemical and pharmaceutical indus-
tries can as well be faced with the need to start and
steer profound transformation processes. This holds
especially true if they redefine their business and
do not only focus on technical innovations but on
their role in creating socio-technical innovations
in the fields they are working for (e.g. mobility,
health, energy production and consumption). To
create socio-technological innovations, chemical
companies must consider themselves as being part
of a wider innovation network with actors from
different sectors and a variety of stakeholders. 
Researchers from the field of transition man-
agement have formulated recommendations on
how managers can prepare their companies for
change – be it evolutionary or revolutionary in kind.
These recommendations may be of value for man-
agers in the chemical and pharmaceutical indus-
try as well (cf. figure 3):
1. Markets & customer requirements
Chemical and pharmaceutical companies need
to have an in-depth understanding of the chang-
ing market requirements on the different activ-
ities in the value chain up to the final consumer
market. Given the diversity and complexity of
the different value chains chemical companies
are involved in, this is a significant challenge.
Companies should have discussion platforms
involving various stakeholders, such as non-gov-
ernmental organizations, as part of an early
warning system in order to detect weak signals
of changing requirements.
2. Strategies & business models
Companies should develop their strategies out-
side-in and work with scenarios. They can thus
guarantee that potential developments are
taken into account and simplistic views of the
future are avoided. With this in mind, strategies
Figure 3 From megatrends to business excellence: Is your company ready?
Evaluate your company’s strategy
and business model:
What is your business strategy
for Asia?
Is your strategy resilient to
changing circumstances?
(e.g. energy and raw material
costs; change in demand/volu-
mes; change of regulation)
Do you check the potential of
business model innovations for
your company? 
Are your competitors working
on business model innovations
that may disrupt the current
rules of the market?
Evaluate your company’s corpo-
rate culture and the skills of your
employees:
Is your corporate culture open
for cooperation? Is your compa-
ny able to cooperate and inno-
vate with other industries and
scientific disciplines beyond
chemistry? 
Is your management team suf-
ficiently diverse (age, gender,
cultural background, expertise,
cross-industry experience)?
Are you able to attract, retain
and develop new employees in
the right quantity and quality? 
Evaluate your company’s corpo-
rate foresight and market intelli-
gence activities:
Do you have a differentiated
idea of potential trends and
their impact on your business? 
Be aware that the impact of
these trends may be either
directly on your business or
come indirectly through diffe-
rent stages of the value chain!
Do you expect radical, disrupti-
ve changes for your customers
that may alter their product
and process requirements?
Does your company have an
early warning system?
Evaluate your company’s proces-
ses and technology:
Are your R&D and production
processes best in class? What
could you learn from the auto-
mobile industry?
What is the influence of the
digitalization on your compa-
ny’s production activities and
the total supply chain? 
What innovations may alter
your business profoundly? Do
you expect innovations in the
field of white, green or red bio-
technology or nanotechnology
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and business models should be tested with
regard to their resilience in the light of chang-
ing circumstances. And ideas for business model
innovations may be collected beyond the chem-
ical and pharmaceutical industry. 
3. Processes & technologies
Production assets, IT-systems and processes in
the field of innovation, production and market-
ing should be investigated with regard to their
flexibility. Of course, this is hard to be achieved
in the chemical and pharmaceutical industry
with its high capital intensity and regulatory
framework. But in times of increasing volatili-
ty, flexibility of resources is a company goal per
se and may lead to investments in multi-pur-
pose assets. 
4. Corporate culture & employees
Corporate cultures in the chemical and phar-
maceutical industry will have to open up, so that
opportunities of the globalization and innova-
tion across industries and scientific disciplines
can be realized. With regard to employee qual-
ification, in-depth knowledge of chemistry and
engineering will, of course, be of crucial impor-
tance for the success of chemical and pharma-
ceutical companies in the future as well. How-
ever, at the same time, more employees with
intercultural, interdisciplinary and knowledge
from other industries are needed.
5 Conclusion
Companies in the chemical and pharmaceuti-
cal industry in Germany have to focus on their abil-
ity to change – even if they consider the upcoming
change to be more evolutionary than revolution-
ary in character. First, they should continue to opti-
mize their current business in order to secure their
competitiveness. Second, they should anticipate
potential disruptive changes early and work on
their value creation capabilities through innova-
tion. And third, they may identify new innovation
paths by focusing on the larger socio-technical sys-
tems they are working for. The transition taking
place in different societal fields such as mobility,
food supply, health, environmental protection opens
up new opportunities for companies in the chem-
ical and pharmaceutical industry to position them-
selves in these newly emerging networks and to
create new viable business models. Thus, the ten-
sion between the “exploitation of current assets
and capabilities” and the „exploration of new pos-
sibilities“ through innovation, cooperation and new
alliances characterizes the fundamental manage-
ment challenge for companies in the chemical and
pharmaceutical industry in Germany on their way
“From megatrends to business excellence”. 
Note:The data used within this article results from
a study jointly conducted by the University of Mün-
ster, the Provadis School of International Manage-
ment and Technology, the association VCI, the con-
sulting firm PWC strategy& and the CHEManager.
The corresponding publication and further infor-
mation can be found at www.chempharmtrends.de.
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